Last Updated on October 15, 2024 by The Health Master
Glenmark Pharmaceuticals has received final approval by the United States Food and Drug Administration (USFDA) for diltiazem hydrochloride extended release capsules USP, 60 mg, 90 mg, and 120 mg.
This is the generic version of Cardizem1 SR extended release capsules, 60 mg, 90 mg, and 120 mg, of Biovail Laboratories.
Glenmark has been granted a competitive generic therapy (CGT) designation for Diltiazem hydrochloride extended release capsules USP, 60 mg, 90 mg, and 120 mg, therefore, with this approval, Glenmark is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing.
According to IQVIATM sales data for the 12 month period ending January 2021, the Cardizem SR extended release capsules, 60 mg, 90 mg, and 120 mg market achieved annualsales of approximately
$56.7 million.
Glenmark’s current portfolio consists of 170 products authorised for distribution in the US marketplace and 42 ANDA’s pending approval with the USFDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Also read related news:
Strides gets USFDA nod for Potassium Chloride for oral solution
Pharma Companies recall these drugs in US
AstraZeneca gets DCGI approval for Osimertinib tablets
Lupin launches generic Nitazoxanide tablets
Dr Reddy’s gets 3 observations from USFDA for US-based API plant
World’s most expensive drug, costs ₹18 crore per dose
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
